Drugs / MRX-6
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00867607 | Mar 2011 → Apr 2013 | allergic contact dermatitis | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT02031445 | Aug 2014 → Mar 2015 | atopic eczema | Celsus Therapeutics PLC | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2015-02-17 | AKARI Therapeutics | Results Celsus Therapeutics Announces That the Phase II Trial of MRX-6 Cream 2% in Pediatric Atopic Dermatitis Did Not Reach Primary Endpoint akaritx.com ↗ |
| 2015-01-12 | AKARI Therapeutics | Regulatory Celsus Therapeutics Announces FDA Allowance of IND for Clinical Development of MRX-6 Cream in Atopic Dermatitis akaritx.com ↗ |
| 2014-06-17 | AKARI Therapeutics | Regulatory Celsus Therapeutics Plc Receives Approval from the Ministry of Health of Israel For Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients akaritx.com ↗
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis. |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRX-6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00867607 ↗ |
| Route | Topical | “topical MRX-6 Cream 2%” NCT02031445 ↗ |